Literature DB >> 22808988

Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care.

A Ganesan1, E M Krantz, K Huppler Hullsiek, M S Riddle, A C Weintrob, T Lalani, J F Okulicz, M Landrum, B Agan, T J Whitman, M J Ross, N F Crum-Cianflone.   

Abstract

OBJECTIVES: As socioeconomic factors may impact the risk of chronic kidney disease (CKD), we evaluated the incidence and risk factors of incident CKD among an HIV-infected cohort with universal access to health care and minimal injecting drug use (IDU).
METHODS: Incident CKD was defined as an estimated glomerular filteration rate (eGFR) <60 ml/min/1.73 m(2) for ≥ 90 days. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Rates were calculated per 1000 person-years (PY). Associations with outcomes were assessed using two separate Cox proportional hazard models, adjusting for baseline and time-updated covariates.
RESULTS: Among 3360 participants [median age 29 years; 92% male; 44% African American (AA)] contributing 23,091 PY of follow-up, 116 developed incident CKD [5.0/1000 PY; 95% confidence interval (CI) 4.2-6.0/1000 PY]. The median first eGFR value was 97.0 mL/min/1.73 m(2) [interquartile range (IQR) 85.3-110.1 mL/min/1.73 m(2)]. Baseline factors associated with CKD included older age, lower CD4 count at HIV diagnosis [compared with CD4 count ≥ 500 cells/μL, hazard ratio (HR) 2.1 (95% CI 1.2-3.8) for CD4 count 350-499 cells/μL; HR 3.6 (95% CI 2.0-6.3) for CD4 count 201-349 cells/μL; HR 4.3 (95% CI 2.0-9.4) for CD4 count ≤ 200 cells/μL], and HIV diagnosis in the pre-highly active antiretroviral therapy (HAART) era. In the time-updated model, low nadir CD4 counts, diabetes, hepatitis B, hypertension and less HAART use were also associated with CKD. AA ethnicity was not associated with incident CKD in either model.
CONCLUSIONS: The low incidence of CKD and the lack of association with ethnicity observed in this study may in part be attributable to unique features of our cohort such as younger age, early HIV diagnosis, minimal IDU, and unrestricted access to care. Lower baseline CD4 counts were significantly associated with incident CKD, suggesting early HIV diagnosis and timely introduction of HAART may reduce the burden of CKD.
© 2012 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22808988     DOI: 10.1111/j.1468-1293.2012.01036.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  10 in total

1.  Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy.

Authors:  Sarah Razzak Chaudhary; Biruh T Workeneh; Maria E Montez-Rath; Andrew R Zolopa; Paul E Klotman; Wolfgang C Winkelmayer
Journal:  Nephrol Dial Transplant       Date:  2015-07-13       Impact factor: 5.992

2.  Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Authors:  Pedro Rodríguez Quesada; Laura López Esteban; Jimena Ramón García; Rocío Vázquez Sánchez; Teresa Molina García; Gabriel Gaspar Alonso-Vega; Javier Sánchez-Rubio Ferrández
Journal:  Int J Clin Pharm       Date:  2015-05-26

3.  Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  A C Achhra; A Mocroft; M J Ross; L Ryom; G M Lucas; H Furrer; J Neuhaus; C Somboonwit; M Kelly; J M Gatell; C M Wyatt
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

4.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

5.  Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4.

Authors:  Engi F Attia; Kathleen M Akgün; Cherry Wongtrakool; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; David Rimland; Sheldon T Brown; Guy W Soo Hoo; Joon Kim; Patty J Lee; Lynn M Schnapp; Amir Sharafkhaneh; Amy C Justice; Kristina Crothers
Journal:  Chest       Date:  2014-12       Impact factor: 9.410

6.  The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status.

Authors:  Michelle M Estrella; Man Li; Adrienne Tin; Alison G Abraham; Michael G Shlipak; Sudhir Penugonda; Shehnaz K Hussain; Frank J Palella; Steven M Wolinsky; Jeremy J Martinson; Rulan S Parekh; W H Linda Kao
Journal:  Clin Infect Dis       Date:  2014-10-03       Impact factor: 9.079

Review 7.  Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis.

Authors:  Udeme E Ekrikpo; Andre P Kengne; Aminu K Bello; Emmanuel E Effa; Jean Jacques Noubiap; Babatunde L Salako; Brian L Rayner; Giuseppe Remuzzi; Ikechi G Okpechi
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

8.  Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.

Authors:  Nongodo Firmin Kaboré; Armel Poda; Jacques Zoungrana; Ollo Da; Laura Ciaffi; Aoua Semdé; Issouf Yaméogo; Adrien B Sawadogo; Eric Delaporte; Nicolas Meda; Sophie Limou; Amandine Cournil
Journal:  BMC Nephrol       Date:  2019-05-07       Impact factor: 2.388

9.  Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis.

Authors:  Ruizi Shi; Xiaoxiao Chen; Haijiang Lin; Yingying Ding; Na He
Journal:  BMC Nephrol       Date:  2022-03-17       Impact factor: 2.388

10.  Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.

Authors:  R Hsu; L Brunet; J Fusco; A Beyer; G Prajapati; C Wyatt; M Wohlfeiler; G Fusco
Journal:  HIV Med       Date:  2020-11-28       Impact factor: 3.180

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.